Novartis’s $1.5B ADC Acquisition Highlights Growing Pharma Demand, Benefiting VERAXA Biotech

Novartis has agreed to acquire Myricx Bio for $1.1 billion upfront, with up to $400 million in milestone payments, reinforcing strong pharmaceutical demand for next-generation antibody-drug conjugate (“ADC”) technologies. The deal, announced this week, gives Novartis access to Myricx’s novel N-myristoyltransferase inhibitor (“NMTi”) payload platform and two lead ADC programs.

The latest transaction adds to a growing list of multibillion-dollar ADC and T-cell engager (“TCE”) deals, highlighting continued strategic investment in differentiated antibody platforms. Recent major deals include Gilead Sciences’ acquisition of Tubulis and Jazz Pharmaceuticals’ collaboration with AbCellera, among others.

VERAXA Biotech (NASDAQ: VRXA) operates in one of biotechnology’s most active partnering environments, with pharmaceutical companies continuing to commit billions of dollars to differentiated antibody therapeutics. The company is advancing proprietary antibody therapeutics spanning both ADCs and TCEs through its patented BiTAC platform, positioning it within two therapeutic categories that continue to attract significant pharmaceutical investment, strategic collaborations and acquisition activity.

According to the press release, VERAXA’s BiTAC platform enables the development of bispecific T cell engagers, bispecific ADCs and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research.

The Novartis-Myricx deal reflects continued industry demand for innovative antibody technologies capable of addressing limitations of existing cancer therapies. For VERAXA shareholders, this trend signals potential value as the company’s pipeline progresses toward clinical development. VERAXA’s focus on both ADCs and TCEs places it at the intersection of two high-demand areas in oncology.

As pharmaceutical giants seek to bolster their oncology portfolios through acquisitions and partnerships, companies like VERAXA with differentiated platforms may become attractive targets. The company’s BiTAC technology, which combines ADC and TCE capabilities, offers a unique approach that could address multiple cancer types.

For more information on VERAXA Biotech, visit the company’s newsroom at http://ibn.fm/VRXA.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Novartis’s $1.5B ADC Acquisition Highlights Growing Pharma Demand, Benefiting VERAXA Biotech.

The post Novartis’s $1.5B ADC Acquisition Highlights Growing Pharma Demand, Benefiting VERAXA Biotech appeared first on citybuzz.